½ÃÀ庸°í¼­
»óǰÄÚµå
1620760

¼¼°èÀÇ 1Â÷ ¼¼Æ÷ ½ÃÀå : À¯·¡, ¼¼Æ÷ À¯Çü, ÃÖÁ¾»ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Primary Cells Market by Origin (Animal Primary Cells, Human Primary Cells), Cell Type (Dermatocytes, Gastrointestinal Cells, Heart Cells), End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 190 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

1Â÷ ¼¼Æ÷ ½ÃÀåÀº 2023³â¿¡ 14¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 16¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 12.10%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 31¾ï 8,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

1Â÷ ¼¼Æ÷ ½ÃÀåÀº »ý¸í °úÇп¡¼­ ¼¼Æ÷ »ý¸®Çаú ÀǾàǰ °³¹ß ¿¬±¸¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÔÀ¸·Î½á Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. °Ç¼¼Æ÷ ±ÕÁÖ¿¡ ºñÇØ º¸´Ù º»°ÝÀûÀÎ »ý¹°ÇÐ ¿¬±¸¿¡ ÇʼöÀûÀÔ´Ï´Ù. ¿ëµµ´Â ¾Ï ¿¬±¸, ½ÉÀåÇ÷°ü ¿¬±¸, ½Å°æ °úÇÐ µî ´Ù¹æ¸é ¶ÇÇÑ ÃÖÁ¾ »ç¿ëÀÚ´Â ¿¬±¸±â°ü, Á¦¾àȸ»ç, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ÀÌ Áß½ÉÀÔ´Ï´Ù. ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ±Þ¼ºÀåÇÏ´Â Àç»ý ÀÇ·á ºÎ¹®Àº 1Â÷ ¼¼Æ÷°¡ »õ·Î¿î Ä¡·á È常¦ °³¹ßÇÏ´Â Áß¿äÇÑ ¿ä¼Ò°¡ µÇ¾î Å« »ç¾÷ ±âȸ¸¦ °¡Á®¿É´Ï´Ù. À¯Áö¿¡ ÇÊ¿äÇÑ ³ôÀº ºñ¿ëÀ̳ª µ¿¹°À̳ª Àΰ£ À¯·¡ÀÇ ¼¼Æ÷¿ø¿¡ °üÇÑ À±¸®ÀûÀÎ ¿ì·Á°¡ ½ÃÀå ¼ºÀåÀÇ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ³ôÀº È¿À² ÀÌ·¯ÇÑ µµ±¸¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. °æÀïÀ» À¯ÁöÇϱâ À§ÇØ ±â¾÷ÀÌ ÀÌ·¯ÇÑ ºÎ¹®¿¡ ÅõÀÚÇÏ´Â °ÍÀÌ À¯ÀÍÇÑ °ÍÀ¸·Î °£Áֵ˴ϴÙ. Áö½ÄÀ» ¸ðÀ¸´Â °Í ÀϺΠÁ¦ÇÑÀ» ±Øº¹ÇÏ´Â µ¥ µµ¿òÀÌ µÇ¸ç, ±× °á°ú ÇöÀç ¿ëµµ¸¦ È®ÀåÇÏ°í °³¹ßÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ (2023³â) 14¾ï 3,000¸¸ ´Þ·¯
ÃßÁ¤³â (2024³â) 16¾ï ´Þ·¯
¿¹Ãø³â (2030³â) 31¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 12.10%

½ÃÀå ¿ªÇÐ: ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â 1Â÷¼¼Æ÷ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

1Â÷ ¼¼Æ÷ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ºñÁî´Ï½º ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¾à¹° ½ºÅ©¸®´× ¹× ¼¼Æ÷ ±â¹Ý ºÐ¼®¿¡¼­ÀÇ ¼ö¿ë È®´ë
    • ±âŸ ±âÁ¸ ¹æ¹ý¿¡ ºñÇØ ÃÊ´ë Àΰ£ ¼¼Æ÷ÀÇ ÀåÁ¡
    • ´ÜŬ·ÐÇ×ü¿Í ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿À¿° µîÀÇ ÀϹÝÀûÀÎ ¼¼Æ÷ ¹è¾ç ¹®Á¦
  • ½ÃÀå ±âȸ
    • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿Í ¹ÙÀÌ¿ÀÀǾàǰ»ê¾÷ È®´ë
    • 1Â÷ ¼¼Æ÷¸¦ ÀÌ¿ëÇÑ »ý¹° ÀÇ·á ¿¬±¸ÀÇ ÁøÀü
  • ½ÃÀåÀÇ °úÁ¦
    • ¼¼Æ÷ »ý¹°ÇÐ ¿¬±¸ ºÎ¹®ÀÇ À±¸®Àû ¹®Á¦

Porter's Five Force: 1Â÷ ¼¼Æ÷ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force ÇÁ·¹ÀÓ ¿öÅ©´Â 1Â÷ ¼¼Æ÷ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ÀÛ¾÷Àº ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¸°ÔÇÏ¸é ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : 1Â÷ ¼¼Æ÷ ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº 1 Â÷ ¼¼Æ÷ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¸¦ Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : 1Â÷ ¼¼Æ÷ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

1Â÷ ¼¼Æ÷ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ½ÇÀûÀ» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁß, ºÎ¹®È­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í, º¥´õ´Â °æÀïÀÌ °ÝÈ­µÇ´Â °¡¿îµ¥ ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ßÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º: 1Â÷ ¼¼Æ÷ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â 1Â÷ ¼¼Æ÷ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±âº» °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ: 1Â÷ ¼¼Æ÷ ½ÃÀå¿¡¼­ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â

1Â÷ ¼¼Æ÷ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ¸¶·ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ ´Ù·ç´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®¿¡¼­ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ¼³¸íÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, »ê¾÷ÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡µµ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¾à¹° ½ºÅ©¸®´× ¹× ¼¼Æ÷ ±â¹Ý ºÐ¼®ÀÇ º¸±Þ
      • ±âÁ¸ ¹æ¹ý¿¡ ºñÇØ Àΰ£ ÃÊ´ë¼¼Æ÷ÀÇ ÀåÁ¡
      • ´ÜŬ·ÐÇ×ü¿Í ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÁÖ¸ñÀÌ ³ô¾ÆÁø´Ù
    • ¾ïÁ¦¿äÀÎ
      • ¿À¿° µîÀÇ ÀϹÝÀûÀÎ ¼¼Æ÷ ¹è¾çÀÇ ¹®Á¦
    • ±âȸ
      • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿Í ¹ÙÀÌ¿ÀÀǾàǰ»ê¾÷ È®´ë
      • 1Â÷ ¼¼Æ÷¸¦ »ç¿ëÇÑ »ý¹°ÀÇÇÐ ¿¬±¸ÀÇ Áøº¸
    • °úÁ¦
      • ¼¼Æ÷ »ý¹°ÇÐ ¿¬±¸ ºÎ¹®ÀÇ À±¸®Àû ¹®Á¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • À¯·¡ : Àΰ£ÀÇ ¼¼Æ÷ ¹ÝÀÀÀ» Á¤È®ÇÏ°Ô Ç¥ÇöÇϱâ À§ÇÑ Àΰ£ÀÇ 1Â÷ ¼¼Æ÷¿¡ ´ëÇÑ ÃëÇâÀÇ °íÁ¶
    • °Ç¼¼Æ÷ À¯Çü: ÀǾàǰ °³¹ß ¹× µ¶¼º °Ë»ç¿¡¼­ ÇǺΠ°Ç¼¼Æ÷ äÅà Áõ°¡
    • ÃÖÁ¾ »ç¿ëÀÚ : ½ÇÇè Áß Á¤È®ÇÑ °á°ú¸¦ º¸ÀåÇϱâ À§ÇØ »ý¸í °úÇÐ ±â¾÷¿¡¼­ 1Â÷ ¼¼Æ÷ »ç¿ëÀÌ ±ÞÁõ
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå 1Â÷ ¼¼Æ÷ ½ÃÀå : À¯·¡º°

  • ¼Ò°³
  • µ¿¹°
  • Àΰ£

Á¦7Àå 1Â÷ ¼¼Æ÷ ½ÃÀå : ¼¼Æ÷ À¯Çüº°

  • ¼Ò°³
  • ÇǺμ¼Æ÷
  • ¼ÒÈ­°ü ¼¼Æ÷
  • ½ÉÀå¼¼Æ÷
  • Á¶Ç÷¼¼Æ÷
  • °£¼¼Æ÷
    • µ¿°áº¸Á¸ °£¼¼Æ÷
    • ½Å¼±ÇÑ °£¼¼Æ÷
  • Æó¼¼Æ÷
  • ±Ù°ñ°Ý¼¼Æ÷
  • ½Å¼¼Æ÷

Á¦8Àå 1Â÷ ¼¼Æ÷ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼Ò°³
  • »ý¸í°úÇбâ¾÷
  • ¿¬±¸±â°ü

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ 1Â÷ ¼¼Æ÷ ½ÃÀå

  • ¼Ò°³
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ 1Â÷ ¼¼Æ÷ ½ÃÀå

  • ¼Ò°³
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ 1Â÷ ¼¼Æ÷ ½ÃÀå

  • ¼Ò°³
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • CN Bio¿Í LifeNet Health LifeSciences°¡ Á¦ÈÞÇØ, ¹Ì¼Ò»ý¸®ÇÐ ½Ã½ºÅÛ¿ëÀÇ °ËÁõÀÌ ³¡³­ ÃÊ´ë Àΰ£ ¼¼Æ÷¸¦ °ø±Þ
    • AnaBios°¡ Cell Systems¸¦ ÀμöÇØ, â¾àÀ» À§ÇÑ Àΰ£ ¼¼Æ÷ Æ÷Æ®Æú¸®¿À¸¦ È®´ë
    • Human Cell DesignÀÌ 1Çü°ú 2Çü ´ç´¢º´ Á¶»ç¿¡¼­ »õ·Î¿î ¹ß°ßÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ¼±ÁøÀûÀÎ Àΰ£ º£Å¸ ¼¼Æ÷ ¸ðµ¨, Endoc-BH5¸¦ ¹ß¸Å
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Biopredic International
  • Corning Incorporated
  • Danaher Corporation
  • FUJIFILM Irvine Scientific, Inc.
  • Lonza AG
  • PromoCell GmbH
  • Reachbio LLC
  • Sciencell Research Laboratories, Inc.
  • Sekisui Xenotech, LLC
  • Stem Cell Technologies, Inc.
  • StemExpress, LLC
  • The Bio Convergence Company
  • The Merck Group
  • Thermo Fisher Scientific, Inc.
  • Zenbio, Inc.
JHS 25.01.06

The Primary Cells Market was valued at USD 1.43 billion in 2023, expected to reach USD 1.60 billion in 2024, and is projected to grow at a CAGR of 12.10%, to USD 3.18 billion by 2030.

The market for primary cells is expanding significantly, driven by their essential role in life sciences for studying cellular physiology and drug development. Primary cells are directly obtained from living tissues, retaining native functions and genetics, which makes them indispensable for more authentic biological research compared to cell lines. Their necessity spans across biomedical research, drug discovery, and tissue engineering due to their relevance in mimicking in vivo conditions. Applications are extensive including cancer research, cardiovascular studies, and neuroscience, with end-users predominantly comprising research institutes, pharmaceutical companies, and biotechnology firms. Key growth influencers in the primary cells market include advancements in biotechnology, a heightened focus on personalized medicine, and increasing government funding for cell-based research. The burgeoning field of regenerative medicine presents substantial opportunities, with primary cells serving as a crucial component for developing novel therapeutic candidates. However, market growth is challenged by the high costs of cell isolation and maintenance and the ethical concerns regarding animal and human-derived cell sources. Technological innovations such as 3D cell cultures and CRISPR gene editing could provide breakthroughs, offering more cost-effective and efficient tools for researchers. It would be beneficial for companies to invest in these areas to stay competitive. Multi-center collaborations and partnerships with academic institutions can help overcome some limitations by pooling resources and knowledge, thus expanding the current applications and expediting development. One of the key areas for innovation is in creating standardized and affordable primary cell lines that can reduce variability and enhance reproducibility of research outcomes. The market is dynamic and competitive, requiring businesses to stay adaptive to new scientific discoveries and technological advancements to maintain growth and relevance in the field.

KEY MARKET STATISTICS
Base Year [2023] USD 1.43 billion
Estimated Year [2024] USD 1.60 billion
Forecast Year [2030] USD 3.18 billion
CAGR (%) 12.10%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Primary Cells Market

The Primary Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing acceptance in drug screening and cell based assays
    • Advantages of primary human cells over other existing methods
    • Growing focus on monoclonal antibodies and personalized medicine
  • Market Restraints
    • Common cell culture problems such as contamination
  • Market Opportunities
    • Expanding biotechnology and biopharmaceutical industries
    • Advancements in biomedical research using primary cells
  • Market Challenges
    • Ethical issues in cell biology research field

Porter's Five Forces: A Strategic Tool for Navigating the Primary Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Primary Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Primary Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Primary Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Primary Cells Market

A detailed market share analysis in the Primary Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Primary Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Primary Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Primary Cells Market

A strategic analysis of the Primary Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Primary Cells Market, highlighting leading vendors and their innovative profiles. These include Biopredic International, Corning Incorporated, Danaher Corporation, FUJIFILM Irvine Scientific, Inc., Lonza AG, PromoCell GmbH, Reachbio LLC, Sciencell Research Laboratories, Inc., Sekisui Xenotech, LLC, Stem Cell Technologies, Inc., StemExpress, LLC, The Bio Convergence Company, The Merck Group, Thermo Fisher Scientific, Inc., and Zenbio, Inc..

Market Segmentation & Coverage

This research report categorizes the Primary Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Origin, market is studied across Animal Primary Cells and Human Primary Cells.
  • Based on Cell Type, market is studied across Dermatocytes, Gastrointestinal Cells, Heart Cells, Hematopoietic Cells, Hepatocytes, Lung Cells, Musculoskeletal Cells, and Renal Cells. The Hepatocytes is further studied across Cryopreserved Hepatocytes and Fresh Hepatocytes.
  • Based on End-User, market is studied across Life Science Companies and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing acceptance in drug screening and cell based assays
      • 5.1.1.2. Advantages of primary human cells over other existing methods
      • 5.1.1.3. Growing focus on monoclonal antibodies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Common cell culture problems such as contamination
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding biotechnology and biopharmaceutical industries
      • 5.1.3.2. Advancements in biomedical research using primary cells
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical issues in cell biology research field
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Origin: Increasing preference for human primary cells for accurate representations of human cellular responses
    • 5.2.2. Cell Type: Rising adoption of dermatocytes in drug development and toxicity testing
    • 5.2.3. End-User: Proliferating use of primary cells in life science companies to ensure accurate results during experimentation
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Primary Cells Market, by Origin

  • 6.1. Introduction
  • 6.2. Animal Primary Cells
  • 6.3. Human Primary Cells

7. Primary Cells Market, by Cell Type

  • 7.1. Introduction
  • 7.2. Dermatocytes
  • 7.3. Gastrointestinal Cells
  • 7.4. Heart Cells
  • 7.5. Hematopoietic Cells
  • 7.6. Hepatocytes
    • 7.6.1. Cryopreserved Hepatocytes
    • 7.6.2. Fresh Hepatocytes
  • 7.7. Lung Cells
  • 7.8. Musculoskeletal Cells
  • 7.9. Renal Cells

8. Primary Cells Market, by End-User

  • 8.1. Introduction
  • 8.2. Life Science Companies
  • 8.3. Research Institutes

9. Americas Primary Cells Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Primary Cells Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Primary Cells Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. CN Bio and LifeNet Health LifeSciences Partner to Supply Validated Primary Human Cells for Microphysiological Systems
    • 12.3.2. AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery
    • 12.3.3. Human Cell Design Launches Endoc-BH5, an Advanced Human Beta Cell Model enabling New Discoveries in Type 1 and 2 Diabetes Research
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biopredic International
  • 2. Corning Incorporated
  • 3. Danaher Corporation
  • 4. FUJIFILM Irvine Scientific, Inc.
  • 5. Lonza AG
  • 6. PromoCell GmbH
  • 7. Reachbio LLC
  • 8. Sciencell Research Laboratories, Inc.
  • 9. Sekisui Xenotech, LLC
  • 10. Stem Cell Technologies, Inc.
  • 11. StemExpress, LLC
  • 12. The Bio Convergence Company
  • 13. The Merck Group
  • 14. Thermo Fisher Scientific, Inc.
  • 15. Zenbio, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦